Clinical trials: Mouth Neoplasms
Follicular Lymphoma
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
This study evaluates the safety and efficacy of combining the EZH2 inhibitor tazemetostat with rituximab in R/R FL subjects previously treated with at least 2 standard prior systemic treatment regimens where at least 1…
- Trial name
- NCT04762160
- Testing
- Tazemetostat, Rituximab
- Where
- 20 sites in United States
- Volunteers
- 5 people
- Sponsor
- Epizyme, Inc.
Multiple Myeloma
Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma
The primary objective of this study is to determine the safety profile, tolerability, and maximum tolerated dose of ixazomib citrate (MLN9708) when taken orally on a weekly dosing schedule by patients with relapsed and refractory…
- Trial name
- NCT00963820
- Testing
- Ixazomib citrate
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Hepatocellular Carcinoma
Clemizole HCl for Subjects With Hepatocellular Carcinoma
This study is a phase IIa open label pilot study of up to six months treatment with clemizole hydrochloride (200 mg vs. 300 mg vs. 400 vs.
- Trial name
- NCT03069508
- Testing
- Clemizole Hydrochloride
- Where
- Turkey (Türkiye)
- Volunteers
- 12 people
- Sponsor
- Eiger Group International, Inc.
Malignant Advanced Solid Tumor
Safety, Tolerability and Pharmacokinetics of Simmiparib in Patients With Malignant Advanced Solid Tumor
Phase I dose escalating trial. Primary objectives of this study are to assess the safety and tolerability of Simmiparib following single and multiple oral doses in patients with advanced solid malignancies, to determine the…
- Trial name
- NCT02993913
- Testing
- Simmiparib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Acebright Pharmaceuticals Co., Ltd.
Arthritis, Rheumatoid
Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors
This study will test if CP-690,550 is safe and effective in rheumatoid arthritis patients taking methotrexate who have an inadequate response to tumor necrosis factor inhibitor treatment.
- Trial name
- NCT00960440
- Testing
- CP-690,550
- Where
- 92 sites in United States, Australia and 12 more
- Volunteers
- 399 people
- Sponsor
- Pfizer
Advanced Solid Tumors
Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules
This is a study to evaluate the effect of high-fat meal on the pharmacokinetics of TQ-B3139 capsules in patients with solid tumor
- Trial name
- NCT04675060
- Testing
- TQ-B3139 capsules
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
This study is a an open-label, multinational, multicenter, single-arm Phase Ⅰb/Ⅱ Study to Evaluate Efficacy and Safety of Oral HH2853 in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma.
- Trial name
- NCT06909877
- Testing
- HH2853 Tablets
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Advanced Solid Metastatic Tumor
Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors
Open, non-randomised, radiolabelled, single centre study with a total of six patients with solid metastatic tumors to determine the rates and routes of elimination of 14C-AZD2171 and its metabolites.
- Trial name
- NCT00503412
- Testing
- AZD2171
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- AstraZeneca
Malignant Melanoma
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
This is an open-label, multicenter, single-agent, phase II study of continuous oral Zelboraf (vemurafenib) in participants with locally-advanced, unresectable, stage IIIc or metastatic melanoma and activating exon 15 BRAF…
- Trial name
- NCT01586195
- Testing
- Vemurafenib
- Where
- 15 sites in United States
- Volunteers
- 31 people
- Sponsor
- Genentech, Inc.
Solid Tumors
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
Phase I, open study to assess the effect of rifampicin, a marketed drug, on how the body handles the experimental drug cediranib in patients with advanced cancer.
- Trial name
- NCT00750841
- Testing
- cediranib
- Where
- 6 sites in Canada, United Kingdom
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors
Evaluate the Safety of BEL-X-HG in Advanced Cancer Patients
This is a Phase I, open-label, uncontrolled, multicenter dose escalation and extension study to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate safety / tolerability and preliminary…
- Trial name
- NCT03256331
- Testing
- BEL-X-HG
- Where
- 2 sites in Taiwan
- Volunteers
- 23 people
- Sponsor
- Belx Bio-Pharmaceutical (Taiwan) Corporation
Carcinoid Syndrome, Carcinoid
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to…
- Conditions
- Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
- Trial name
- CAREFNDR (NCT07087054)
- Testing
- Paltusotine
- Where
- 72 sites in United States, Argentina and 12 more
- Volunteers
- 141 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Multiple Myeloma
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM relapse (cancer has come back) or become non- responsive to treatment and remission gets shorter…
- Trial name
- NCT04570631
- Testing
- Eftozanermin alfa, Bortezomib, Dexamethasone
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 4 people
- Sponsor
- AbbVie
Breast Cancer
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer.
- Trial name
- NCT06206837
- Testing
- vepdegestrant, PF-07220060
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 71 people
- Sponsor
- Pfizer
Acute Myeloid Leukemia (AML)
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: PKC412 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of daunorubicin and cytarabine by making cancer cells more sensitive to the drugs.
- Trial name
- NCT00093600
- Testing
- cytarabine, daunorubicin hydrochloride, midostaurin
- Where
- 6 sites in United States, Germany
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Malignancies
A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies
This study is being carried out to see how single and multiple doses of cediranib are handled by the body (that is how they are absorbed, broken down and got rid of from the body) by measuring levels of drug in the blood in…
- Trial name
- NCT00981721
- Testing
- cediranib (RECENTIN TM, AZD2171)
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Generalized Myasthenia Gravis, gMG
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine…
- Trial name
- OCTAGON (NCT07221838)
- Testing
- Oral Corticosteroid Tapering Schedule, Ravulizumab, Prednisone/Prednisolone
- Where
- 12 sites in United States, Germany and 2 more
- Volunteers
- 75 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Glioblastoma, Giant Cell Glioblastoma
Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
The purpose of this study is to determine the highest safe dose of XL184 administered orally in combination with temozolomide (TMZ, Temodar®) and radiation therapy (RT).
- Conditions
- Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
- Trial name
- NCT00960492
- Testing
- XL184, temozolomide, Radiation Therapy
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- Exelixis
Solid Tumors, Hematologic Malignancies
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with advanced solid tumors.
- Conditions
- Solid Tumors, Hematologic Malignancies, Myelodysplastic Syndrome
- Trial name
- NCT00741234
- Testing
- SB939, Azacitidine
- Where
- 5 sites in United States, Singapore
- Volunteers
- 85 people
- Sponsor
- S*BIO
B-Cell Malignancies
Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
This is a first-in-human (FIH), multicenter, open-label Phase I dose escalation study to evaluate the safety and preliminary efficacy of the TT-01488 tablet, a non-covalent reversible BTK inhibitor, for the treatment of adult…
- Trial name
- NCT05275504
- Testing
- TT-01488
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.